Dedee Murrell News Today

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer-- Industry veterans and leading academic experts ...

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer

The British Journal of Dermatology Publishes Results from Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 25,...

During the first 2 months of life, changes in skin biomarkers were predictive of whether children would develop atopic dermatitis up to 2 years later.

Elevated TARC at 2 months more than quadrupled the likelihood of moderate-severe AD at 2 years

Researchers in Israel have shown that a new machine-learning tool can speed up the diagnosis of psoriatic arthritis (PsA) by up to 4 years, potentially preventing irreversible joint damage and deteriorating function for sufferers.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Plus: First-in-class drug shows promise in AD, BTK inhibitor active in pemphigus

Share this article Share this article SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference. "I am pleased to present the t...